Adhera Therapeutics Inc. (ATRX)

Overview

Adhera Therapeutics, Inc. is a pioneering biotech entity dedicated to the advancement of small molecule drugs through the stages of discovery, development, and commercialization. It embarked on its journey under the name Marina Biotech, Inc., transforming its identity to Adhera Therapeutics, Inc. in October 2018. Centrally located in Baton Rouge, Louisiana, the company has positioned itself as a key player in the biotechnological industry with its focus on addressing complex diseases such as Parkinson's disease and Type 1 diabetes through its innovative therapeutic developments.

Products and Services

• MLR-1019 for Parkinson's Disease

A forefront project for Adhera Therapeutics is MLR-1019, which is being developed as a promising treatment option for patients suffering from Parkinson's disease. This therapeutic agent represents the company's commitment to harnessing the power of small molecule drugs to tackle neurological disorders, offering potential improvements in the quality of life for those affected.

• MLR-1023 for Type 1 Diabetes

The second major initiative, MLR-1023, is targeting the treatment of Type 1 diabetes, highlighting the company's versatile approach in combating auto-immune diseases through advanced therapeutic solutions. By focusing on this innovative treatment, Adhera Therapeutics underscores its dedication to contributing significantly to the diabetes care domain, potentially revolutionizing the way Type 1 diabetes is managed.